Research  >  Areas of focus  >  Research platforms  >  Evaluative Clinical Sciences  >  Scientists

Evaluative Clinical Sciences

SRI Platforms

Dr. Jennifer Rabin


Sunnybrook Health Sciences Centre
2075 Bayview Ave., Room M6 178
Toronto, ON
M4N 3M5

Phone: 416-480-6100, ext. 83737


  • B.Sc., 2005, psychology, Dalhousie University, Canada
  • MA, 2009, clinical psychology (neuropsychology), York University, Canada
  • PhD, 2015, clinical psychology (neuropsychology), York University
  • Postdoctoral fellowship, 2018, Massachusetts General Hospital/Harvard Medical School, U.S.

Appointments and Affiliations:

Research Foci:

Research Summary:

Dr. Rabin’s research has two primary directions. As the neuropsychology lead in the Harquail Centre for Neuromodulation, her research characterizes cognitive and behavioural changes associated with novel neuromodulation strategies. This includes low-intensity focused ultrasound (FUS) to open up the blood-brain barrier in patients with Alzheimer’s disease, and high-intensity FUS to treat severe psychiatric and neurological conditions, like depression, obsessive-compulsive disorder and tremor.

Another line of her research combines multimodal imaging like MRI and positron emission tomography with sensitive cognitive measures to understand better modifiable risk factors for Alzheimer’s disease. Her work specifically focuses on vascular health and physical activity. This research is carried out in collaboration with SRI senior scientist Dr. Sandra Black and colleagues at Massachusetts General Hospital.

Selected Publications:

See current publications list at PubMed.

  1. Rabin JS, Klein H, Kirn DR, Schultz AP, Yang HS, Hampton O, Jiang S, Buckley RF, Viswanathan A, Hedden T, Pruzin J, Yau WY, Guzman-Velez E, Quiroz YT, Properzi M, Marshall GA, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP. Physical activity moderates the association of amyloid burden on longitudinal cognitive decline and neurodegeneration. JAMA Neurol. In press.
  2. Buckley RF, Mormino EC, Rabin JS, Hohman T, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ, Shultz AP, Kirn DR, Scott MR, Hedden T, Farrell M, Price J, Chhatwal JP, Rentz DM, Villemagne VL, Johnson KA, Sperling RA. Sex differences in the association between regional tau and global amyloid PET. JAMA Neurol. 2019 May 1;76(5):542–551. doi: 10.1001/jamaneurol.2018.4693.
  3. Rabin JS, Perea R, Buckley RF, Neal TE, Buckner RL, Johnson KA, Sperling RA, Hedden T. Global white matter diffusion characteristics predict longitudinal cognitive change independently from amyloid status in clinically normal older adults. Cereb Cortex. 2019 Mar 1;29(3):1251–62.
  4. Rabin JS, Yang HS, Schultz AP, Hanseeuw BJ, Marshall GA, Hedden T, Kilpatrick E, Klein H, Buckley RF, Properzi MJ, Rao V, Kirn DR, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP. Vascular risk and β-amyloid are synergistically associated with cortical tau. Ann Neurol. 2019 Feb;85(2):272–79.
  5. Rabin JS, Schultz AP, Hedden T, Viswanathan A, Marshall GA, Kilpatrick E, Klein H, Buckley RF, Yang HS, Properzi M, Rao V, Kirn DR, Papp KV, Rentz DM, Johnson KA, Sperling RA, Chhatwal JP. Interactive associations of vascular risk and β-amyloid burden with cognitive decline in clinically normal elderly individuals: findings from the Harvard Aging Brain Study. JAMA Neurol. 2018 Sep 1;75(9):1124–31.

Related News and Stories: